COMP vs DFTX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COMP and DFTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COMP and DFTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Compass, Inc. is a tech-enabled residential real estate company that operates an owned-brokerage model in the United States. It recruits real estate agents onto a proprietary software platform that handles marketing, client management, and transaction workflow, and it earns revenue primarily as a share of the sales commissions its agents generate when homes change hands. Because agents keep most of each commission under negotiated splits, Compass keeps only a thin slice of a very large revenue number, so its margins are structurally low and its results track the volume of home sales closely. The company has expanded into adjacent services such as title, escrow, and mortgage referrals to capture more of each transaction.

Full COMP guide

Definium Therapeutics (Nasdaq: DFTX) is a clinical-stage biopharmaceutical company focused on brain-health and psychiatric disorders. It is the rebranded MindMed, having changed its name from Mind Medicine (MindMed) Inc. in January 2026. Its lead asset is DT120 ODT (formerly MM120), a proprietary orally disintegrating tablet formulation of lysergide (LSD) tartrate being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD), alongside DT402, an earlier-stage candidate in autism spectrum disorder (ASD). In June 2026 the company reported that its Phase 3 Emerge trial of DT120 in MDD met its primary and key secondary endpoints, and in September 2026 it reported that Panorama, a second Phase 3 trial in GAD, also met its primary endpoint. A pre-NDA meeting with the FDA is scheduled for the fourth quarter of 2026, with an NDA submission planned for the first half of 2027.

Full DFTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COMP drivers: Scale and market leadership; Improving profitability.
• DFTX drivers: Late-stage psychiatry pipeline; Large unmet-need markets.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Compass is highly exposed to the housing cycle: when mortgage rates rise or home sales slow, commission revenue falls quickly while many costs remain, and the stock moves with bond yields (it gained about 6% in a single mid-October session as long-term rates fell). For DFTX, as a pre-revenue clinical-stage company, Definium has no approved products and depends on trial outcomes, FDA decisions, and continued access to capital.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COMP if you believe its drivers more; DFTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COMP and DFTX guides.

COMP. A residential brokerage like Compass reports a very large revenue number, but most of each commission is paid out to agents, so the figures to watch are EBITDA and free cash flow rather than top-line growth alone. The trailing P/E near 156x reflects only a sliver of GAAP profit, while the forward P/E near 11x assumes about $0.84 of EPS, so the valuation depends heavily on whether Anywhere synergies show up. At ~0.7x sales and with 13 analysts carrying a mean target near $14.62, the market is pricing the housing cycle and integration risk more than the scale.

DFTX. Traditional valuation multiples do not apply because Definium has no revenue and reports net losses, with consensus looking for a loss of about $3.18 per share in 2026 and about $1.94 in 2027. The roughly $4.4 billion market value, about 4x the company's ~$1.08 billion cash pile, reflects expectations for DT120's approval and launch. The company has guided that its cash funds operations into 2028, and the next quarterly report is expected around November 5, 2026.

Headline figures (approximate, October 2026): COMP shows revenue (ttm) ~$10.6B (Q2 2026 +109% YoY with Anywhere), net income (ttm) ~$67.5M (~0.6% net margin), margins (ttm) ~14% gross, ~3.8% operating, p/e (trailing / forward) ~156x / ~11x; DFTX shows revenue (ttm) ~$0 (pre-revenue, no approved products), net loss (ttm) ~$354M (Q2 2026 alone ~$159M), eps (q2 2026 actual vs estimate) ~-$1.44 vs ~-$0.55, cash / debt (jun 2026) ~$1.08B / ~$36M.

COMP and DFTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COMP and DFTX exposure against your real portfolio. It is not an investment adviser.